75 related articles for article (PubMed ID: 23268332)
21. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.
Tsitsipatis D; Jayavelu AK; Müller JP; Bauer R; Schmidt-Arras D; Mahboobi S; Schnöder TM; Heidel F; Böhmer FD
Oncotarget; 2017 Apr; 8(16):26613-26624. PubMed ID: 28460451
[TBL] [Abstract][Full Text] [Related]
22. FES kinases are required for oncogenic FLT3 signaling.
Voisset E; Lopez S; Chaix A; Georges C; Hanssens K; Prébet T; Dubreuil P; De Sepulveda P
Leukemia; 2010 Apr; 24(4):721-8. PubMed ID: 20111072
[TBL] [Abstract][Full Text] [Related]
23. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
24. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
[TBL] [Abstract][Full Text] [Related]
25. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
26. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
28. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
Xu B; Shi PC; Song XY; Tang JH; Zhou SY
Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
31. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
32. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia.
Zhong L; Jia YQ; Meng WT; Ni X
Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491
[TBL] [Abstract][Full Text] [Related]
33. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
34. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
35. MSK1 activation in acute myeloid leukemia cells with FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Kano Y; Furukawa Y
Leukemia; 2010 May; 24(5):1087-90. PubMed ID: 20357825
[No Abstract] [Full Text] [Related]
36. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Heidary DK; Huang G; Boucher D; Ma J; Forster C; Grey R; Xu J; Arnost M; Choquette D; Chen G; Zhou JH; Yao YM; Ball ED; Namchuk M; Davies RJ; Henkel G
J Med Chem; 2012 Jan; 55(2):725-34. PubMed ID: 22221201
[TBL] [Abstract][Full Text] [Related]
37. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
[TBL] [Abstract][Full Text] [Related]
38. SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Puissant A; Fenouille N; Alexe G; Pikman Y; Bassil CF; Mehta S; Du J; Kazi JU; Luciano F; Rönnstrand L; Kung AL; Aster JC; Galinsky I; Stone RM; DeAngelo DJ; Hemann MT; Stegmaier K
Cancer Cell; 2014 Feb; 25(2):226-42. PubMed ID: 24525236
[TBL] [Abstract][Full Text] [Related]
39. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML.
Nemes Z; Takács-Novák K; Völgyi G; Valko K; Béni S; Horváth Z; Szokol B; Breza N; Dobos J; Szántai-Kis C; Illyés E; Boros S; Kok RJ; Őrfi L
Bioorg Med Chem Lett; 2018 Aug; 28(14):2391-2398. PubMed ID: 29935772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
